Q. In a recent article about the challenges of treating eczema (atopic dermatitis), you described a number of over-the-counter treatments as well as modern prescription medicines. In particular, you ...

June 7 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA), opens new tab and Regeneron Pharmaceuticals Inc's (REGN.O), opens new tab anti-inflammation drug Dupixent ...

Sanofi and Regeneron’s Dupixent is already approved to treat eczema in kids as young as 6 years old—and it’s well on its way to becoming a $10 billion drug. Armed with a trial win in even younger ...

Rivals are closing in on Sanofi and Regeneron’s Dupixent. With AbbVie’s Rinvoq having already bested Dupixent in atopic dermatitis, Pfizer has now chalked up its own efficacy win over the blockbuster ...

Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.

ABBV's Rinvoq demonstrated strong efficacy to treat eczema. This put REGN's Dupixent in its cross hairs. Safety concerns could hurt Rinvoq's ability to take meaningful share away from Dupixent. REGN ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved its blockbuster medicine Dupixent (dupilumab) for a new indication — moderate-to-severe atopic dermatitis (AD) or eczema in ...

(HealthDay News) — Dupixent (dupilumab) has been approved by the US Food and Drug Administration to treat moderate-to-severe eczema that isn’t well controlled by topical medication. The active ...

Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...

Sanofi SNY and partner Regeneron REGN announced positive data from pivotal phase III study evaluating their blockbuster drug, Dupixent (dupilumab), to treat moderate-to-severe atopic dermatitis (“AD”) ...

Danielle Jonas spoke to Insider about her experience with moderate eczema. Jonas said she was "uncomfortable with myself," before using Dupixent as a treatment for her condition. Because of her eczema ...